Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

Pharma Sector Update - Ample catalysts to sustain luster - HDFC Securities

Posted On: 2021-01-13 23:16:41 (Time Zone: Arizona, USA)

Ms. Bansi Desai, Institutional Research Analyst, HDFC Securities

We see several growth catalysts across key markets and product categories (inhalers, biosimilars, complex injectables) playing out over the next 2-3 years for Indian pharma companies. The investments made over the last few years leave them well placed to capitalise on these opportunities. With cost bases pruned and operating leverage benefits, the sector is poised to grow at ~21% earnings CAGR and witness ROCE improvement of 430bps to 15% over FY20- 23e. This, coupled with strong balance sheets (near debt-free), should support valuations, in our view. BSE HC Index has outperformed Nifty by ~47% in the past one year and trades at ~29x 1-yr forward, ~30% above its historical average and ~22% premium to Nifty (vs. 10-yr average of 31%).

India biz remains attractive; chronic leads, vitamins strength could sustain: While chronic therapies continue to lead (Torrent, Lupin, Cipla to benefit), we see Vitamins as a promising therapy that could sustain higher growth, led by Covid induced changes in nutrition awareness and habits. The recovery in acute therapies will further consolidate market share gains for companies with strong therapeutic presence and leading brands (Alkem).

Progress on complex pipeline in US augurs well for growth and profitability: The share of injectables, specialty, biosimilars, and complex products in US revenues is expected to increase from ~22% in FY20 to ~33% in FY23e, for our covered universe. Improving quality of pipeline in the US will not only ensure that the growth rates hold up better but will also drive higher profitability.

API business sees the turn of fortunes, PLI benefits a few years away: The strong performance in 1HFY21 (21% YoY for the covered universe) was driven by factors such as customer stocking, pricing/currency benefits, which have largely normalised. However, the broader demand environment remains strong, driven by structural tailwinds (supply chain de-risk, PLI scheme), and is likely to drive healthy growth over the next few years. PLI scheme benefits are a few years away and will majorly benefit MSME players. Sun, Aurobindo, Lupin are likely to have participated, among covered companies.

Covid vaccine monetisation offers upside potential, not factored in estimates: Vaccine monetisation can add material cash flows, although upsides will be for limited period and contingent on several variables (pricing, competition, capacity). We see three possible ways of monetising with varying degree of lucrativeness: a) develop/ manufacture own vaccine; b) undertake third party manufacturing; c) distribute vaccines. Among covered companies, Aurobindo, Cadila and Dr. Reddy's are in the race to monetize this opportunity.

Cost savings, moderating investments to drive return ratios higher: Investments in R&D/capex have peaked and are likely to be more targeted towards complex filings/capabilities going forward. With cost bases rationalised, operating leverage benefits will drive margin expansion of ~350bps over FY20- 23e. We expect sector RoCE to improve by 430bps to ~15% in the same period.

Top picks are Alkem, Aurobindo, Cipla and Lupin: We like Alkem (the best play on acute recovery), Aurobindo (building complex pipeline, Covid upsides), Cipla (strong India franchise, inhalers monetisation) and Lupin (chronic focused portfolio, inhalers, operating leverage).

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Easy Trip Planners Ltd. - IPO - Strong Financials - Reliance Securities

Bharat Forge - Initiating Coverage - Constant evolution - HDFC Securities

Mahindra Logistics - Large-ticket deal win - ICICI Securities

Company Update - Huhtamaki India - ICICI Direct

Gladiator Stocks: IndusInd Bank, VIP Industries - ICICI Direct

Warehousing demand expected to grow around 160% to reach 35 million sq. ft in 2021: JLL

Telecom - Spectrum auction: Prudent investment by Bharti Airtel - ICICI Securities

JB Chemicals & Pharmaceuticals - Analyst meet takeaways - ICICI Securities

IPO Review - MTAR Technologies Ltd - ICICI Direct

Auto Sector - Monthly Volume Round-up - Feb 21 - Decent YoY Growth Continues

Aditya Birla Fashion and Retail - Focus on scaling up new businesses - ICICI Securities

Automobiles (wholesale) - Wholesales push continues despite modest retail trends - ICICI Securities

Aditya Birla Capital - Thoughtful (inclusive) conglomerate business evolution commands premium - ICICI Securities

Jubilant Foodworks - Buying in-the-money options - ICICI Securities

Multi Commodity Exchange of India - Play on rising commodity prices? - ICICI Securities

Gladiator Stocks - Sudarshan Chemical - ICICI Direct

Monthly Commodities Outlook - March 2021 - ICICI Direct

ICICI Direct - Monthly Currency Outlook: Rupee to depreciate further towards 75.00 level...

ICICI Direct - Covid Recovery Pulse - E-way bill generation in February 2021 starts on strong note...

Company Update - Virtual JLR Investor Event - Tata Motors - ICICI Direct

Analyst Meet Update - Aditya Birla Fashion and Retail - ICICI Direct

MTAR Technologies Ltd. - IPO - Huge Opportunities from Clean Energy Bodes Well - Reliance Research

ICICI Direct Derivatives Weekly View (February 26): Failure to move above 14700 may extend declines towards 14300...

Bank: Sector Credit Trends - Slows, Yet again - HDFC Securities

Piramal Enterprises - Pharma day highlights - ICICI Securities

Polymer price tracker - PVC prices rise sharply again! - ICICI Securities

Greenply Industries - Growth returns, at an inflection point - ICICI Securities

Tata Motors - JLR future proofing itself with rapid electric transition - ICICI Securities

Dairy - Higher freight cost and increase in Global SMP prices - ICICI Securities

Analyst Meet Update - Nestlé India (Hold): Focus on product innovation, expanding rural reach - ICICI Direct

MTAR Technologies Ltd - A strong player in booming high precision engineering... - Geojit

Rollover Report for February - March 2021 : Angel Broking

Reaction from industry experts on Q3FY21 GDP numbers

M. Govinda Rao, Chief Economic Adviser, Brickwork ratings on Q3FY21 GDP numbers

Mr. Dhiraj Relli, MD & CEO, HDFC securities views on Q3FY21 GDP Growth Number

Suman Chowdhury, Chief Analytical Officer, Acuité Ratings & Research on Q3FY21 GDP

Rollover Analysis - Feb 21, 2021 - YES Securities

Consumer Durables - Demand-driven recovery continues - HDFC Securities

Cement - Demand surprises; earnings upgrade to continue - ICICI Securities

Gladiator Stocks - TeamLease Services - ICICI Direct

Gladiator Stocks - Metals to outshine post multi-year breakout... - ICICI Direct

Company Update - Sundaram Finance - ICICI Direct

Indian pharmaceutical industry to meet an ambition of US$130 billion by 2030 through innovation-led growth: EY-FICCI report

4th Industrial Conclave - Bullish undertone, favourable valuation - HDFC Securities

Sanofi India - Weak quarter; sequential improvement - ICICI Securities

Sunteck Realty - All eyes on upcoming launches - ICICI Securities

Company Update - Tata Motors - ICICI Direct

Q4CY20 Company Update - Mahindra CIE Automotive - ICICI Direct

Event Update - Hindalco - ICICI Direct

EY report launch at BioAsia 2021 - Moving the needle: Healthcare industry in a post-COVID world

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020